ClinicalTrials.gg
CompletedNCT02558231TRITONUpdated Mar 30, 2025Results posted

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

A Phase 3 interventional study of Macitentan and Tadalafil in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 58 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.

Enrollment
4th of 12
247 · median 67
Started
2016
the only one that year
Phase 3
6 of 12
1 open now
Registered
4th of 12
by date
Lead sponsor
9 of 12
Actelion

Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 6 in phase 3, and was the 4th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About selexipag

selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing selexipag in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed prior to any study-mandated procedure.
  2. Male or female ≥ 18 and ≤ 75 years of age at screening.
  3. Initial PAH diagnosis \< 6 months prior to enrollment.
  4. RHC performed between Day -28 and Day 1, meeting all the following criteria:

    • Mean pulmonary artery pressure (mPAP) ≥ 25 mmHg.
    • Pulmonary artery wedge pressure or left ventricular end-diastolic pressure ≤ 15 mmHg.
    • PVR ≥ 480 dyn•sec/cm5 (≥ 6 Wood Units).
    • Negative vasoreactivity test mandatory in idiopathic, heritable, and drug/toxin induced PAH (at this or a previous RHC).
  5. Symptomatic PAH belonging to one of the following subgroups:

    • Idiopathic.
    • Heritable.
    • Drug or toxin induced.
    • Associated with one of the following: connective tissue disease; infection; congenital heart disease.
  6. 6-minute walk distance (6MWD) ≥ 50 m at screening.
  7. Women of must not be pregnant, must perform regular pregnancy tests, and use reliable .

Exclusion criteria

Exclusion Criteria:

  1. Any PAH-specific drug therapy at any time.
  2. Cardio pulmonary rehabilitation program based on exercise (planned, or started ≤ 12 weeks prior to Day 1).
  3. (BMI) > 40 kg/m2 at screening.
  4. Presence of three or more of the following risk factors for heart failure with preserved at screening:

    • BMI > 30 kg/m2.
    • Diabetes mellitus of any type.
    • Essential hypertension.
    • Coronary artery disease, i.e., any of the following:

      • History of stable angina or
      • More than 50% stenosis in a coronary artery (by coronary angiography) or
      • History of myocardial infarction or
      • History of or planned coronary artery bypass grafting and/or coronary artery stenting.
  5. Acute myocardial infarction ≤ 12 weeks prior to screening.
  6. Stroke ≤ 12 weeks prior to screening.
  7. Known permanent atrial fibrillation.
  8. SBP \< 90 mmHg at screening or Day 1.
  9. Ongoing or planned treatment with organic nitrates and/or doxazosin.
  10. Presence of one or more of the following signs of relevant lung disease at any time up to screening:

    • Diffusing capacity of the lung for carbon monoxide (DLCO) \< 40% of predicted (eligible only if no or mild interstitial lung disease on computed tomography).
    • Forced vital capacity (FVC) \< 60% of predicted.
    • (FEV1) \< 60% of predicted.
  11. Known or suspected pulmonary veno-occlusive disease (PVOD).
  12. Documented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total > 3 × (ULN) accompanied by (AST) > ULN (assessed by central laboratory at screening); and/or Class C.
  13. Serum AST and/or alanine aminotransferase (ALT) > 3 × ULN (assessed by central laboratory at screening).
  14. Severe renal impairment (estimated ≤ 30 mL/min/1.73 m2) assessed by central laboratory at screening.
  15. Ongoing or planned dialysis.
  16. \< 100 g/L assessed by central laboratory at screening.
  17. Known or suspected uncontrolled thyroid disease (hypo- or hyperthyroidism).
  18. Loss of vision in one or both eyes because of non-arteritic ischemic optic neuropathy (NAION).
  19. Treatment with strong inducers of cytochrome P450 3A4 (; e.g., carbamazepine, rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's wort) ≤ 28 days prior to Day 1.
  20. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir) and/or strong inhibitors of CYP2C8 (e.g., gemfibrozil) ≤ 28 days prior to Day 1.
  21. Treatment with another drug (planned, or taken ≤ 12 weeks prior to Day 1).
  22. to any of the 3 study treatments or any of their formulations.
  23. Pregnancy, breastfeeding, or intention to become pregnant during the study.
  24. Concomitant life-threatening disease with a \< 12 months.
  25. Alcohol abuse.
  26. Any factor or condition likely to affect protocol compliance of the subject, as judged by the investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Triple oral combination treatment

    Macitentan, tadalafil, and selexipag

    Drug: Macitentan · Drug: Tadalafil · Drug: Selexipag

  • Placebo comparator
    Dual oral combination treatment

    Macitentan, tadalafil, and placebo

    Drug: Macitentan · Drug: Tadalafil

Interventions

  • Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.

  • Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.

  • Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR)

    Change from baseline to Week 26 in PVR was expressed as the ratio of Week 26 to baseline PVR value (Week 26 divided by baseline) using re-calculated PVR. PVR was determined by right heart catheterization (RHC). A geometric least square mean ratio of Week 26 to baseline PVR less than (\<) 1 corresponds to a reduction in PVR from baseline. Missing values were imputed using a last observation carried forward (LOCF) approach.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD)

    The change from baseline to Week 26 in 6MWD was calculated as Week 26 minus baseline. The test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. Missing values were imputed using a LOCF approach.

    Time frame: Baseline, Week 26

  2. Change From Baseline to Week 26 in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) Levels

    The change from baseline to Week 26 in NT-proBNP was expressed as the ratio of Week 26 to baseline NT-proBNP (Week 26 divided by baseline). A geometric least square mean ratio of Week 26 to baseline NT-proBNP \<1 corresponds to a reduction in NT-proBNP from baseline. Missing values were imputed using a LOCF approach.

    Time frame: Baseline, Week 26

  3. Percentage of Participants With Absence of Worsening From Baseline to Week 26 in World Health Organization (WHO) Functional Class (FC)

    WHO FC is a classification graded from Class I to IV which reflects disease severity based on symptoms. Worsening was defined as death or hospitalization due to PAH. Class I: No limitation of activity; Class II: slight limitation with ordinary activities; Class III: may not have symptoms at rest but greatly limited activities; Class IV: symptoms at rest and inability to carry out any physical activity without symptoms. Missing values were imputed using a LOCF approach.

    Time frame: Week 26

  4. Change From Baseline to Week 26 in Mean Pulmonary Arterial Pressure (mPAP)

    Change from baseline to Week 26 in mean Pulmonary Arterial Pressure (mPAP) was measured. The pulmonary artery pressure is a measure of the blood pressure found in the main pulmonary artery. Missing values were imputed using a LOCF approach.

    Time frame: Baseline, Week 26

  5. Change From Baseline to Week 26 in Mean Right Atrial Pressure (mRAP)

    Change from baseline to Week 26 in mean Right Atrial Pressure (mRAP) was measured. Missing values were imputed using a LOCF approach.

    Time frame: Baseline, Week 26

  6. Change From Baseline to Week 26 in Total Pulmonary Resistance

    Change from baseline to Week 26 in total pulmonary resistance was measured. Total pulmonary resistance was calculated as mPAP/CO\*80, where CO is cardiac output. Re-calculated values were used for analysis and missing values were imputed using a LOCF approach.

    Time frame: Baseline, Week 26

  7. Change From Baseline to Week 26 in Cardiac Index

    Change from baseline to Week 26 in cardiac index was measured. Cardiac index is the amount of blood pumped by the heart, per minute, per meter square of body surface area. Re-calculated values were used for analysis and missing values were imputed using a LOCF approach.

    Time frame: Baseline, Week 26

  8. Change From Baseline to Week 26 in Venous Oxygen Saturation (%)

    Change from baseline to Week 26 in venous oxygen saturation was measured. Missing values were imputed using a LOCF approach.

    Time frame: Baseline, Week 26

  9. Number of Participants With Disease Progression Event

    Number of participants with disease progression event were reported. Disease progression event as adjudicated by the CEC, defined as any of the following: a. Death (all causes; adjudicated for PAH relationship); b. Hospitalization for worsening PAH; c. Initiation of prostacyclin, a prostacyclin analog, or a prostacyclin receptor agonist for worsening PAH; d. Clinical worsening defined as a post-baseline decrease in 6MWD by more than (\>) 15 percent (%) from the highest 6MWD obtained at or after baseline, accompanied by WHO FC III or IV (both conditions confirmed at two consecutive post-baseline visits separated by 1-21 days).

    Time frame: Week 26, Month 12, Month 18, Month 24, Month 30, and End of Analysis Period (up to 40 months)

07

Results

Posted Sep 11, 2020
Limitations and caveats
The main limitation of the sponsor's findings was that analyses of disease progression and mortality were exploratory due to the testing hierarchy and the post hoc nature of the analyses. The study was not powered to show significant differences for the disease progression related endpoint. Another limitation was the availability of hemodynamic assessments only for Week 26 timepoint.

Participant flow

Participant flow — Overall Study
MilestoneTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Started123124
Treated123123
Completed9898
Not completed2526
Withdrew: Death412
Withdrew: Lost to follow-up74
Withdrew: Withdrawal by subject74
Withdrew: Physician decision75
Withdrew: Sponsor decision01

Outcome measures

PrimaryChange From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR)

Change from baseline to Week 26 in PVR was expressed as the ratio of Week 26 to baseline PVR value (Week 26 divided by baseline) using re-calculated PVR. PVR was determined by right heart catheterization (RHC). A geometric least square mean ratio of Week 26 to baseline PVR less than (\<) 1 corresponds to a reduction in PVR from baseline. Missing values were imputed using a last observation carried forward (LOCF) approach.

Time frame:
Baseline, Week 26
Reported as:
Geometric least squares mean · ratio
Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR)
ratioTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR)0.46 (0.422 to 0.503)0.48 (0.441 to 0.526)
Statistical analysis
  • Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo) · ANCOVA · p = 0.4239 · Ratio of geometric least square mean: 0.96 · 95% CI 0.86 to 1.07
SecondaryChange From Baseline to Week 26 in 6-minute Walk Distance (6MWD)

The change from baseline to Week 26 in 6MWD was calculated as Week 26 minus baseline. The test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. Missing values were imputed using a LOCF approach.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · meter
Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD)
meterTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD)54.96 (40.419 to 69.501)56.39 (41.447 to 71.327)
Statistical analysis
  • Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo) · ANCOVA · p = 0.8758 · Least square (ls) mean difference: -1.43 · 95% CI -19.393 to 16.538
SecondaryChange From Baseline to Week 26 in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) Levels

The change from baseline to Week 26 in NT-proBNP was expressed as the ratio of Week 26 to baseline NT-proBNP (Week 26 divided by baseline). A geometric least square mean ratio of Week 26 to baseline NT-proBNP \<1 corresponds to a reduction in NT-proBNP from baseline. Missing values were imputed using a LOCF approach.

Time frame:
Baseline, Week 26
Reported as:
Geometric least squares mean · ratio
Change From Baseline to Week 26 in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) Levels
ratioTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Change From Baseline to Week 26 in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) Levels0.26 (0.206 to 0.328)0.25 (0.200 to 0.320)
Statistical analysis
  • Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo) · ANCOVA · p = 0.8529 · Ratio of geometric ls mean: 1.03 · 95% CI 0.770 to 1.371
SecondaryPercentage of Participants With Absence of Worsening From Baseline to Week 26 in World Health Organization (WHO) Functional Class (FC)

WHO FC is a classification graded from Class I to IV which reflects disease severity based on symptoms. Worsening was defined as death or hospitalization due to PAH. Class I: No limitation of activity; Class II: slight limitation with ordinary activities; Class III: may not have symptoms at rest but greatly limited activities; Class IV: symptoms at rest and inability to carry out any physical activity without symptoms. Missing values were imputed using a LOCF approach.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Worsening From Baseline to Week 26 in World Health Organization (WHO) Functional Class (FC)
percentage of participantsTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Percentage of Participants With Absence of Worsening From Baseline to Week 26 in World Health Organization (WHO) Functional Class (FC)99.297.5
SecondaryChange From Baseline to Week 26 in Mean Pulmonary Arterial Pressure (mPAP)

Change from baseline to Week 26 in mean Pulmonary Arterial Pressure (mPAP) was measured. The pulmonary artery pressure is a measure of the blood pressure found in the main pulmonary artery. Missing values were imputed using a LOCF approach.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline to Week 26 in Mean Pulmonary Arterial Pressure (mPAP)
millimeters of mercury (mmHg)Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Change From Baseline to Week 26 in Mean Pulmonary Arterial Pressure (mPAP)-12.92 (-14.609 to -11.235)-12.20 (-13.881 to -10.515)
Statistical analysis
  • Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo) · ANCOVA · p = 0.4998 · Ls mean difference: -0.72 · 95% CI -2.834 to 1.386
SecondaryChange From Baseline to Week 26 in Mean Right Atrial Pressure (mRAP)

Change from baseline to Week 26 in mean Right Atrial Pressure (mRAP) was measured. Missing values were imputed using a LOCF approach.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 26 in Mean Right Atrial Pressure (mRAP)
mmHgTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Change From Baseline to Week 26 in Mean Right Atrial Pressure (mRAP)-1.78 (-2.512 to -1.045)-1.69 (-2.429 to -0.955)
Statistical analysis
  • Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo) · ANCOVA · p = 0.8528 · Ls mean difference: -0.09 · 95% CI -1.003 to 0.830
SecondaryChange From Baseline to Week 26 in Total Pulmonary Resistance

Change from baseline to Week 26 in total pulmonary resistance was measured. Total pulmonary resistance was calculated as mPAP/CO\*80, where CO is cardiac output. Re-calculated values were used for analysis and missing values were imputed using a LOCF approach.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · dynes*second per centimeter^5
Change From Baseline to Week 26 in Total Pulmonary Resistance
dynes*second per centimeter^5Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Change From Baseline to Week 26 in Total Pulmonary Resistance-511.88 (-569.36 to -454.40)-514.28 (-571.45 to -457.11)
Statistical analysis
  • Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo) · ANCOVA · p = 0.9474 · Ls mean difference: 2.40 · 95% CI -69.368 to 74.178
SecondaryChange From Baseline to Week 26 in Cardiac Index

Change from baseline to Week 26 in cardiac index was measured. Cardiac index is the amount of blood pumped by the heart, per minute, per meter square of body surface area. Re-calculated values were used for analysis and missing values were imputed using a LOCF approach.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · liters per minute per meter square
Change From Baseline to Week 26 in Cardiac Index
liters per minute per meter squareTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Change From Baseline to Week 26 in Cardiac Index0.97 (0.814 to 1.130)0.84 (0.684 to 0.997)
Statistical analysis
  • Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo) · ANCOVA · p = 0.1902 · Ls mean difference: 0.13 · 95% CI -0.066 to 0.328
SecondaryChange From Baseline to Week 26 in Venous Oxygen Saturation (%)

Change from baseline to Week 26 in venous oxygen saturation was measured. Missing values were imputed using a LOCF approach.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percentage of oxygen saturation
Change From Baseline to Week 26 in Venous Oxygen Saturation (%)
percentage of oxygen saturationTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Change From Baseline to Week 26 in Venous Oxygen Saturation (%)5.59 (4.370 to 6.801)6.79 (5.561 to 8.020)
Statistical analysis
  • Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo) · ANCOVA · p = 0.1227 · Ls mean difference: -1.20 · 95% CI -2.737 to 0.327
SecondaryNumber of Participants With Disease Progression Event

Number of participants with disease progression event were reported. Disease progression event as adjudicated by the CEC, defined as any of the following: a. Death (all causes; adjudicated for PAH relationship); b. Hospitalization for worsening PAH; c. Initiation of prostacyclin, a prostacyclin analog, or a prostacyclin receptor agonist for worsening PAH; d. Clinical worsening defined as a post-baseline decrease in 6MWD by more than (\>) 15 percent (%) from the highest 6MWD obtained at or after baseline, accompanied by WHO FC III or IV (both conditions confirmed at two consecutive post-baseline visits separated by 1-21 days).

Time frame:
Week 26, Month 12, Month 18, Month 24, Month 30, and End of Analysis Period (up to 40 months)
Reported as:
Count of participants · Participants
Number of Participants With Disease Progression Event
ParticipantsTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
Week 26813
Month 121320
Month 181523
Month 241525
Month 301627
End of Analysis Period (up to 40 months)1627
Statistical analysis
  • Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo) · Log Rank · p = 0.0867 · Hazard ratio (hr): 0.59 · 95% CI 0.32 to 1.09

Adverse events

Collected over Up to 42 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag)4/119 (3.4%)58/119 (48.7%)118/119 (99.2%)
Double Oral Therapy (Macitentan, Tadalafil, and Placebo)12/127 (9.4%)48/127 (37.8%)119/127 (93.7%)
Most frequent serious events
Showing 10 of 184
Most frequent serious events
EventTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
PneumoniaInfections and infestations8/1194/127
Pulmonary Arterial HypertensionRespiratory, thoracic and mediastinal disorders8/1198/127
Right Ventricular FailureCardiac disorders6/1198/127
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders6/1195/127
Respiratory FailureRespiratory, thoracic and mediastinal disorders6/1191/127
SyncopeNervous system disorders0/1196/127
DyspnoeaRespiratory, thoracic and mediastinal disorders5/1190/127
SepsisInfections and infestations4/1193/127
AnaemiaBlood and lymphatic system disorders3/1192/127
Iron Deficiency AnaemiaBlood and lymphatic system disorders3/1191/127
Most frequent other events
Showing 10 of 60
Most frequent other events
EventTriple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)
HeadacheNervous system disorders83/11978/127
DiarrhoeaGastrointestinal disorders66/11941/127
NauseaGastrointestinal disorders56/11933/127
Oedema PeripheralGeneral disorders45/11946/127
Pain in ExtremityMusculoskeletal and connective tissue disorders37/11924/127
Pain in JawMusculoskeletal and connective tissue disorders35/11915/127
VomitingGastrointestinal disorders30/11914/127
DyspepsiaGastrointestinal disorders27/11917/127
DizzinessNervous system disorders17/11927/127
FatigueGeneral disorders24/11922/127

Baseline characteristics

Full Analysis Set (FAS) includes all randomized participants.

Age, Continuous
Age, Continuous(years)Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)Total
Mean52.2 ± 13.4851.6 ± 13.9251.9 ± 13.67
Sex: Female, Male
Sex: Female, Male(Participants)Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)Total
Female9394187
Male303060
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)Total
Hispanic or Latino101020
Not Hispanic or Latino106108214
Unknown or Not Reported7613
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)Total
Black or African American5510
American Indian or Alaska Native101
Native Hawaiian or Other Pacific Islander000
Asian7310
White102108210
Other336
Unknown or Not Reported5510
Region of Enrollment
Region of Enrollment(participants)Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag)Double Oral Therapy (Macitentan, Tadalafil, and Placebo)Total
AUSTRALIA224
AUSTRIA9514
BELGIUM257
CANADA111425
DENMARK325
FRANCE459
GERMANY132336
IRELAND101
ITALY5611
NETHERLANDS224
SPAIN213
SWEDEN707
SWITZERLAND112
UNITED KINGDOM325
UNITED STATES5856114
08

Study locations

58 sites
  • Arizona Pulmonary Specialists, LTD
    Phoenix, Arizona 85012, United States
  • UCSD Health Sciences
    La Jolla, California 92093, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Piedmont Pulmonary and Critical Care Research
    Atlanta, Georgia 30309, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky 40202, United States
  • LSU Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins School of Medicine
    Baltimore, Maryland 21205, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111-1552, United States
  • Boston University Medical Center
    Boston, Massachusetts 02118-2526, United States
  • Washington University School of Medicine
    Saint Louis, Michigan 63110, United States
  • University of New Mexico Hospital
    Albuquerque, New Mexico 87106, United States
  • The Christ Hospital
    Cincinnati, Ohio 45219-2906, United States
  • Allegheny General Hospital of Research
    Pittsburgh, Pennsylvania 15212, United States
  • UPMC Presbyterian
    Pittsburgh, Pennsylvania 15213, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-8550, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Royal Prince Albert Hospital
    Camperdown, New South Wales 2050, Australia
  • St. Vincents Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • LKH -Universität Klinkum Graz
    Graz, 8036, Austria
  • Krankenhaus der Elisabethinen Linz
    Linz, 4020, Austria
  • AKH Wien
    Wien, 1090, Austria
  • Hôpital Erasme
    Brussels, 1070, Belgium
  • UZ Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • London Health Sciences Centre - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • University of Toronto
    Toronto, Ontario M5G 2N2, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec
    Quebec City, Quebec G1V 4G5, Canada
  • University of Calgary
    Calgary, T1Y 6J4, Canada
  • University of Ottawa Heart Institute
    Ottawa, K1Y 4W7, Canada
  • Aarhus University Hospital Skejby
    Aarhus, 8200, Denmark
  • Rigshospitalet Copenhagen
    Copenhagen, 2100, Denmark
  • CHU de Bicêtre
    Le Kremlin-Bicêtre, 94270, France
  • Unversitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Universitätsklinikum Giessen
    Giessen, 35392, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Universitätsklinikum Köln
    Köln, 50924, Germany
  • Universitätsklinikum Regensburg
    Regensburg, 93053, Germany
  • Mater Misericordiae University Hospital
    Dublin, D07 R2WY, Ireland
  • Ospedale Sant'Orsola
    Bologna, 40138, Italy
  • VUmc Amsterdam
    Amsterdam, 1081 HV, Netherlands
  • Maastricht University Medical Center
    Maastricht, 6229 HX, Netherlands
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Skånes universitetssjukhus Lund
    Lund, 221 85, Sweden
  • Norrlands universitetssjukhus
    Umeå, 901 85, Sweden
  • Kardiologkliniken
    Uppsala, 751 85, Sweden
  • Universiätsspital Zürich
    Zürich, 8091, Switzerland
  • Golden Jubilee National Hospital
    Clydebank, G81 4DY, United Kingdom
  • The Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
  • Hammersmith Hospital
    London, W12 0HS, United Kingdom
09

References and documents

Publications

  • Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grunig E, Hoeper MM, Martin N, Mathai SC, McLaughlin VV, Perchenet L, Poch D, Saggar R, Simonneau G, Galie N. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2021 Oct 5;78(14):1393-1403. doi: 10.1016/j.jacc.2021.07.057. PubMed 34593120 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Aug 2019, 39 months.

Results were first posted in Sep 2020, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 39 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2015
First posted
Sep 23, 2015
StartActual
May 1, 2016
Primary completionActual
Aug 29, 2019
CompletionActual
Apr 20, 2020
Results first posted
Sep 11, 2020
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02558231
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Sep 23, 2015
Start date
May 1, 2016
Primary completion
Aug 29, 2019
Completion
Apr 20, 2020
Results posted
Sep 11, 2020
Last update
Mar 30, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion